Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114895) titled 'Clinical study of sPD-1 as a novel diagnostic and therapeutic marker for NSCLC immunotherapy with checkpoint inhibitors: a prospective observational cohort study' on Dec. 18, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Nanjing Drum Tower Hospital
Condition:
Patients with locally advanced or metastatic NSCLC
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: NSCLC group:142;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301474
Disclaimer: Curated by HT Syndicati...